Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 1,566Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Brilinta/Brilique

02 2Brilinta/Brilique

PharmaCompass

01

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 1,593

2019 Revenue in Millions : 1,581

Growth (%) : 1

blank

02

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 1,472

2020 Revenue in Millions : 1,593

Growth (%) : -8

blank

03

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 1,358

2021 Revenue in Millions : 1,472

Growth (%) : -8

blank

04

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 1,324

2022 Revenue in Millions : 1,358

Growth (%) : -3

blank

05

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular

Currency : USD

2015 Revenue in Millions : 476

2014 Revenue in Millions : 619

Growth (%) : 30%

blank

06

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2017 Revenue in Millions : 1,079

2016 Revenue in Millions : 839

Growth (%) : 29

blank

07

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular

Currency : USD

2014 Revenue in Millions : 68.20%

2013 Revenue in Millions :

Growth (%) :

blank

08

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2018 Revenue in Millions : 1,321

2017 Revenue in Millions : 1,079

Growth (%) : 22%

blank

09

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2016 Revenue in Millions : 839

2015 Revenue in Millions : 619

Growth (%) : 36

blank

10

Brand Name : Brilinta/Brilique

Ticagrelor

arrow
CPhI India 2024
Not Confirmed

Brand Name : Brilinta/Brilique

arrow
CPhI India 2024
Not Confirmed

Ticagrelor

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2019 Revenue in Millions : 1,581

2018 Revenue in Millions : 1,321

Growth (%) : 20

blank